Obesity

Contrave dispute causes co-marketer tension

Contrave dispute causes co-marketer tension

By

An expert tells MM&M a key issue is whether unsubstantiated benefits were used in marketing efforts.

Weight-loss drug prescriptions rise ... slowly

Weight-loss drug prescriptions rise ... slowly

By

First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

By

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

By

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Evolving views of obesity raise questions about the role of weight-loss drugs

Evolving views of obesity raise questions about the role of weight-loss drugs

By

Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Five things for pharma marketers to know: Monday, December 29

Five things for pharma marketers to know: Monday, December 29

By

FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

By

Category news shows that marketing to the obese may mean marketing to related conditions.

Microbiome linked to obesity

Researchers find that jet lag has an impact on the microscopic level.

Demand for obesity drugs creeps upwards

Demand for obesity drugs creeps upwards

By

Although sales have not skyrocketed, Arena and PBM Express Scripts have seen demand for prescription weight-loss medications rise, and researchers at The Obesity Society find the majority of weight-loss intervention candidates are eligible for prescription weight-loss medications.

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

By

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Takeda backs Contrave with 900 sales reps

Takeda backs Contrave with 900 sales reps

By

Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

By

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

CDC: Every state has an obesity problem

The latest data shows an overall widening of the US.

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Study: move more, eat less, save $500

Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.

J&J, Vivus patent suit ends

J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.

Expanding weightloss drug doesn't wow

An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.

Dr. Oz runs afoul of lawmakers

Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.

OPDP says phentermine site thin on details

OPDP says phentermine site thin on details

By

The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.

FDA pauses Orexigen drug approval

FDA pauses Orexigen drug approval

By

The regulator wants more time to discuss post-marketing requirements.

Obesity cause of knee replacement increase

A study shows that total knee replacement is rising—and occurring in more youthful people. The uptick tracks with the rise in obesity.

Two more obesity meds circle Rx status

Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.

Weight-loss drugs fight it out

Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.

Belviq partners up with phentermine

Arena and Eisai are testing Belviq with appetite suppressant phentermine.

Tot obesity drops, market ceiling still high

Tot obesity drops, market ceiling still high

By

A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.

Weight-loss drugs plateau and expand

Weight-loss drugs plateau and expand

By

Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.

Merck's obesity intervention

The drugmaker's new subsidiary will provide behavior and activity training, among other services.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters